Thus, the most likely explanation for the higher levels of TGF-β1 and VEGF in lung cancer cases may be their elevated platelet counts, rather than higher circulating levels of these proteins in vivo or a higher concentration within platelets. The gene discussed is VEGFA; the disease is lung carcinoma.